Danaher

DHR · NYSE

$224.24−$0.19 (−0.08%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $224.43

About DHR

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

Employees: 58,000
Headquarters: WASHINGTON, Washington Dc
Listed: Dec 10, 1969
Sector: Health Care
Industry: Life Sciences Tools & Services
Website: danaher.com

Leadership

Danaher executives
Name	Title	Since	Age
Steven Rales	—	1983	72
Rainer Blair	—	2014	60
Matthew Mcgrew	—	—	53
Matthew Gugino	—	—	—
Greg Milosevich	—	—	—
Christopher Riley	—	—	51
Julie Sawyer Montgomery	—	—	52
Jose-Carlos Gutierrez-Ramos	—	—	62
Georgeann Couchara	—	—	48
Brian Ellis	—	—	59
R. Bradley Gray	—	—	48
Daniel Raskas	—	—	58
Martin Stumpe	—	—	—
Linda Hefner Filler	—	—	65
Mitchell Rales	—	1983	68
Feroz Dewan	—	—	48
Charles Lamanna	—	—	37
Teri List	—	—	62
A. Shane Sanders	—	—	62
John Schwieters	—	—	85
Alan Spoon	—	—	73
Prof. Raymond Stevens	—	—	61
Elias Zerhouni	—	—	73
John Bedford	—	2023	—

Revenue by product and region

Fiscal year ended Dec 31, 2025: $24.57B total revenue

By product

Recurring$20.13B81.9%
Nonrecurring$4.44B18.1%

By region

North America$10.36B42.2%
High-growth markets$7.02B28.6%
Western Europe$5.94B24.2%
Other developed markets$1.25B5.1%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Danaher suppliers and customers
Company	Relationship	Country	Correlation
Bio-Rad Laboratories A BIO	Supplier	US	0.90
Repligen RGEN	Supplier	US	0.88
Bio-Techne TECH	Customer	US	0.83
Arcturus Therapeutics ARCT	Supplier and customer	US	0.83
DiaSorin SpA DIA.MI	Supplier	IT	0.83
Boreo BOREO.HE	Customer	FI	0.80
Mensch und Maschine MUM.DE	Supplier	DE	0.80
Masimo MASI	Supplier and customer	US	0.77
Fortive FTV	Supplier	US	0.76
Georg Fischer AG	Supplier	—	0.74

Similar companies

Companies in the same industry as Danaher

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.